Cellyan Biotechnology Receives Nasdaq Bid Price Deficiency Notice, Faces Potential Delisting

summarizeSummary

Cellyan Biotechnology Co., Ltd received a Nasdaq notification for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period to avoid potential delisting.

check_boxKey Events

• Nasdaq Bid Price Deficiency

  The company was notified by Nasdaq that its Class A ordinary shares traded below the minimum $1.00 bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).

• Compliance Period Initiated

  Cellyan Biotechnology has 180 calendar days, until July 13, 2026, to regain compliance by having its closing bid price reach at least $1.00 for a minimum of ten consecutive business days.

• Potential for Further Action

  Failure to regain compliance within the initial period may lead to eligibility for an additional 180-day grace period, potentially requiring a reverse share split to meet the bid price requirement.

• No Immediate Delisting

  The notification does not result in immediate delisting, and the company's shares will continue to trade uninterrupted under the symbol "HKPD" during the compliance period.

auto_awesomeAnalysis

Cellyan Biotechnology Co., Ltd has received a formal notification from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement. This is a significant risk event for the company, as continued non-compliance could lead to delisting from the Nasdaq Capital Market. While there is a 180-day compliance period, and potentially an additional grace period, the company will need to take action, possibly including a reverse stock split, to maintain its listing. For a micro-cap company like Cellyan Biotechnology, maintaining a Nasdaq listing is crucial for liquidity and investor visibility, making this a very important development for shareholders.